 Prelude Therapeutics Incs NASDAQ:PRLD share price represents a particularly attractive buying opportunity, and the stock has catalysts in the back half of the year, according to BofA Securities. The Prelude Therapeutics Analyst: Tazeen Ahmad upgraded Prelude Therapeutics from Neutral to Buy and maintained a 60 price target. 